Lupin growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+23.1%+18.9%
EBITDA+66.9%+69.9%
Net Income+62.0%+128.7%
EPS (adj.)+62.6%+131.4%
Total Assets+31.4%+18.7%
Total Equity+30.2%+21.5%
Free Cash Flow—+132.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LUPIN₹1,972.70

Lupin Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹90,192 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+23.1+18.9
EBITDA+66.9+69.9
Net Income+62.0+128.7
EPS (adj.)+62.6+131.4
Total Assets+31.4+18.7
Total Equity+30.2+21.5
Free Cash Flow—+132.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.